H.R. 3

To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES
SEPTEMBER 19, 2019

Mr. PALLONE (for himself, Mr. NEAL, and Mr. SCOTT of Virginia) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.

1 Be it enacted by the Senate and House of Representa-
2 tives of the United States of America in Congress assembled,
3 SECTION 1. SHORT TITLE; TABLE OF CONTENTS.
4 (a) IN GENERAL.—This Act may be cited as the
5 “Lower Drug Costs Now Act of 2019”.

(b) Table of Contents.—The table of contents is as follows:

Sec. 1. Short title; table of contents.

**TITLE I—LOWERING PRICES THROUGH FAIR DRUG PRICE NEGOTIATION**

Sec. 101. Providing for lower prices for certain high-priced single source drugs.
Sec. 102. Selected drug manufacturer excise tax imposed during noncompliance periods.

**TITLE II—MEDICARE PARTS B AND D PRESCRIPTION DRUG INFLATION REBATES**

Sec. 201. Medicare part B rebate by manufacturers.

**TITLE III—PART D IMPROVEMENTS AND MAXIMUM OUT-OF-POCKET CAP FOR MEDICARE BENEFICIARIES**

Sec. 301. Medicare part D benefit redesign.

**TITLE I—LOWERING PRICES THROUGH FAIR DRUG PRICE NEGOTIATION**

**SEC. 101. PROVIDING FOR LOWER PRICES FOR CERTAIN HIGH-PRICED SINGLE SOURCE DRUGS.**

(a) Program to Lower Prices for Certain High-Priced Single Source Drugs.—Title XI of the Social Security Act (42 U.S.C. 1301 et seq.) is amended by adding at the end the following new part:

“PART E—FAIR PRICE NEGOTIATION PROGRAM TO LOWER PRICES FOR CERTAIN HIGH-PRICED SINGLE SOURCE DRUGS

“SEC. 1191. ESTABLISHMENT OF PROGRAM.

“(a) In General.—The Secretary shall establish a Fair Price Negotiation Program (in this part referred to
as the ‘program’). Under the program, with respect to each price applicability period, the Secretary shall—

“(1) publish a list of selected drugs in accordance with section 1192;

“(2) enter into agreements with manufacturers of selected drugs with respect to such period, in accordance with section 1193;

“(3) negotiate and, if applicable, renegotiate maximum fair prices for such selected drugs, in accordance with section 1194; and

“(4) carry out the administrative duties described in section 1196.

“(b) DEFINITIONS RELATING TO TIMING.—For purposes of this part:

“(1) INITIAL PRICE APPLICABILITY YEAR.—The term ‘initial price applicability year’ means a plan year (beginning with plan year 2023) or, if agreed to in an agreement under section 1193 by the Secretary and manufacturer involved, a period of more than one plan year (beginning on or after January 1, 2023).

“(2) PRICE APPLICABILITY PERIOD.—The term ‘price applicability period’ means, with respect to a drug, the period beginning with the initial price applicability year with respect to which such drug is a
selected drug and ending with the last plan year
during which the drug is a selected drug.

“(3) Selected drug publication date.—
The term ‘selected drug publication date’ means,
with respect to each initial price applicability year,
April 15 of the plan year that begins 2 years prior
to such year.

“(4) Voluntary negotiation period.—The
term ‘voluntary negotiation period’ means, with re-
spect to an initial price applicability year with re-
spect to a selected drug, the period—

“(A) beginning on the sooner of—

“(i) the date on which the manufac-
turer of the drug and the Secretary enter
into an agreement under section 1193 with
respect to such drug; or

“(ii) June 15 following the selected
drug publication date with respect to such
selected drug; and

“(B) ending on March 31 of the year that
begins one year prior to the initial price appli-
cability year.

“(e) Other Definitions.—For purposes of this
part:
“(1) Fair price eligible individual.—The term ‘fair price eligible individual’ means, with respect to a selected drug, an individual who is—

“(A) enrolled under a prescription drug plan under part D of title XVIII or an MA–PD plan under part C of such title under which coverage is provided for such drug;

“(B) enrolled under a group health plan or health insurance coverage offered in the group or individual market (as such terms are defined in section 2791 of the Public Health Service Act) with respect to which there is in effect an agreement with the Secretary under section 1197 with respect to such selected drug; or

“(C) entitled to benefits under part A of title XVIII or enrolled under part B of such title.

“(2) Maximum fair price.—The term ‘maximum fair price’ means, with respect to a plan year during a price applicability period and with respect to a selected drug (as defined in section 1192(c)) with respect to such period, the price published pursuant to section 1195 in the Federal Register for such drug and year.
“(3) Average international market price defined.—

“(A) In general.—The terms ‘average international market price’ and ‘AIM price’ mean, with respect to a drug, the average price (which shall be the net average price, if practicable, and volume-weighted, if practicable) for any dosage form and strength of a unit (as defined in subparagraph (C)) for the drug for sales of such drug, as computed (as of the date of publication of such drug as a selected drug under section 1192(a)) in all countries described in clause (ii) of subparagraph (B) that are applicable countries (as described in clause (i) of such subparagraph) with respect to such drug.

“(B) Applicable countries.—

“(i) In general.—For purposes of subparagraph (A), a country described in clause (ii) is an applicable country described in this clause with respect to a drug if there is available an average price for any unit for the drug for sales of such drug in such country.
“(ii) COUNTRIES DESCRIBED.—For purposes of this paragraph, the following are countries described in this clause:

“(I) Australia.
“(II) Canada.
“(III) France.
“(IV) Germany.
“(V) Japan.
“(VI) The United Kingdom.

“(C) UNIT.—The term ‘unit’ means, with respect to a drug, the lowest identifiable quantity (such as a capsule or tablet, milligram of molecules, or grams) of the drug that is dispensed.

“SEC. 1192. SELECTION OF NEGOTIATION-ELIGIBLE DRUGS AS SELECTED DRUGS.

“(a) IN GENERAL.—Not later than the selected drug publication date with respect to an initial price applicability year, the Secretary shall select and publish in the Federal Register a list of—

“(1) at least 25 negotiation-eligible drugs described in subparagraphs (A) and (B), but not subparagraph (C), of subsection (d)(1) (or, with respect to an initial price applicability year beginning after 2023, the maximum number (if such number is less
than 25) of such negotiation-eligible drugs for the
year) with respect to such year; and

“(2) all negotiation-eligible drugs described in
subparagraph (C) of such subsection with respect to
such year.

Each drug published on the list pursuant to the previous
sentence shall be subject to the negotiation process under
section 1194 for the voluntary negotiation period with re-
spect to such initial price applicability year (and the re-
negotiation process under such section as applicable for
any subsequent year during the applicable price applica-
bility period). In applying this subsection, any negotiation-
eligible drug that is selected under this subsection for an
initial price applicability year shall not count toward the
required minimum amount of drugs to be selected under
paragraph (1) for any subsequent year, including such a
drug so selected that is subject to renegotiation under sec-
tion 1194.

“(b) SELECTION OF DRUGS.—In carrying out sub-
section (a)(1) the Secretary shall select for inclusion on
the published list described in subsection (a) with respect
to a price applicability period, the negotiation-eligible
drugs that the Secretary projects will result in the greatest
savings to the Federal Government or fair price eligible
individuals during the price applicability period. In making
this projection of savings for drugs for which there is an
AIM price for a price applicability period, the savings shall
be projected taking into consideration both the volume of
drugs for which payment is made, to the extent such data
is available, and the amount by which the net price for
the drugs exceeds the AIM price for the drugs.

“(c) Selected Drug.—For purposes of this part,
each drug included on the list published under subsection
(a) with respect to an initial price applicability year shall
be referred to as a ‘selected drug’ with respect to such
year and each subsequent plan year beginning before the
first plan year beginning after the date on which the Sec-
retary determines the drug is no longer a qualifying single
source drug.

“(d) Negotiation-Eligible Drug.—

“(1) In General.—For purposes of this part,
the term ‘negotiation-eligible drug’ means, with re-
spect to the selected drug publication date with re-
spect to an initial price applicability year, a qual-
ifying single source drug, as defined in subsection
(e), that meets any of the following criteria:

“(A) Covered Part D Drugs.—The drug
is among the 125 covered part D drugs (as de-
finied in section 1860D–2(e)) for which there
was an estimated greatest net spending under
parts C and D of title XVIII, as determined by
the Secretary, during the most recent plan year
prior to such drug publication date for which
data are available.

“(B) OTHER DRUGS.—The drug is among
the 125 drugs for which there was an estimated
greatest net spending in the United States, as
determined by the Secretary, during the most
recent plan year prior to such drug publication
date for which data are available.

“(C) INSULIN.—The drug is a qualifying
single source drug described in subsection
(e)(3).

“(2) CLARIFICATION.—In determining whether
a qualifying single source drug satisfies any of the
criteria described in paragraph (1), the Secretary
shall, to the extent practicable, use data that is ag-
aggregated across strengths and dosage forms and
routes of administration of the drug.

“(3) PUBLICATION.—Not later than the se-
lected drug publication date with respect to an ini-
tial price applicability year, the Secretary shall pub-
lish in the Federal Register a list of negotiation-eli-
gible drugs with respect to such selected drug publi-
cation date.
“(e) QUALIFYING SINGLE SOURCE DRUG.—For purposes of this part, the term ‘qualifying single source drug’ means any of the following:

“(1) DRUG PRODUCTS.—A drug that—

“(A) is approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act and continues to be marketed pursuant to such approval; and

“(B) is not the listed drug for any drug that is approved and continues to be marketed under section 505(j) of such Act.

“(2) BIOLOGICAL PRODUCTS.—A biological product that—

“(A) is licensed under section 351(a) of the Public Health Service Act, including any product that has been deemed to be licensed under section 351 of such Act pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009, and continues to be marketed under section 351 of such Act; and

“(B) is not the reference product for any biological product that is licensed and continues to be marketed under section 351(k) of such Act.
“(3) INSULIN PRODUCT.—Notwithstanding paragraphs (1) and (2), any insulin product that is approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act or licensed under subsection (a) or (k) of section 351 of the Public Health Service Act and continues to be marketed under such section 505 or 351.

For purposes of applying paragraphs (1)(B) and (2)(B), a drug or biological product that is marketed by the same sponsor or manufacturer (or an affiliate thereof or a cross-licensed producer or distributor) as the listed drug or reference product described in such respective paragraph shall not be taken into consideration.

“(f) INFORMATION ON INTERNATIONAL DRUG PRICES.—For purposes of determining which negotiation-eligible drugs to select under subsection (a) and, in the case of such drugs that are selected drugs, to determine the maximum fair price of such drug and whether such maximum fair price should be renegotiated under section 1194, the Secretary shall use data relating to the AIM price with respect to such drugs as available or provided to the Secretary and shall on an ongoing basis request from manufacturers of selected drugs information on the AIM price of such drugs.
“SEC. 1193. MANUFACTURER AGREEMENTS.

“(a) In General.—For purposes of section 1191(a)(2), the Secretary shall enter into agreements with manufacturers of selected drugs with respect to a price applicability period, by not later than June 15 following the selected drug publication date with respect to such selected drug, under which—

“(1) during the voluntary negotiation period for the initial price applicability year for the selected drug, the Secretary and manufacturer, in accordance with section 1194, negotiate to determine (and, by not later than the last date of such period and in accordance with subsection (c), agree to) a maximum fair price for the selected drug of the manufacturer in order to provide access to such price—

“(A) to fair price eligible individuals described in subparagraph (A) or (B) of section 1191(c)(1) furnished such drug during, subject to subparagraph (2), the price applicability period; and

“(B) to hospitals, physicians, and other providers of services and suppliers with respect to fair price eligible individuals described in subparagraph (C) of such section administered such drug during, subject to subparagraph (2), the price applicability period;
“(2) the Secretary and the manufacturer shall, in accordance with a process and during a period specified by the Secretary pursuant to rulemaking, renegotiate (and, by not later than the last date of such period and in accordance with subsection (c), agree to) the maximum fair price for the drug if the Secretary determines that there is a material change in any of the factors described in section 1194(d) relating to the drug, including changes in the AIM price for the drug, in order to provide access to such maximum fair price (as so renegotiated)—

“(A) to fair price eligible individuals described in subparagraph (A) or (B) of section 1191(c)(1) furnished such drug during any year during the price applicability period (beginning after such renegotiation) with respect to such selected drug; and

“(B) to hospitals, physicians, and other providers of services and suppliers with respect to fair price eligible individuals described in subparagraph (C) of such section administered such drug during any year described in sub-
paragraph (A);

“(3) the maximum fair price (including as renegotiated pursuant to paragraph (2)), with respect
to such a selected drug, shall be provided to fair
price eligible individuals described in subparagraph
(A) or (B) of section 1191(c)(1) at the pharmacy or
by the mail order service at the point-of-sale of such
drug;

“(4) the manufacturer, subject to subsection
(c), submits to the Secretary, in a form and manner
specified by the Secretary—

“(A) for the voluntary negotiation period
for the price applicability period (and, if appli-
cable, before any period of renegotiation speci-
fied pursuant to paragraph (2)) with respect to
such drug all information that the Secretary re-
quires to carry out the negotiation (or renegoti-
ation process) under this part, including infor-
mation described in section 1192(f) and section
1194(d)(1); and

“(B) on an ongoing basis, information on
changes in prices for the drug that would affect
the AIM price for the drug or otherwise provide
a basis for renegotiation of the maximum fair
price of such drug pursuant to paragraph (2);

“(5) the manufacturer agrees that in the case
the selected drug of a manufacturer is a drug de-
scribed in subsection (c), the manufacturer will, in
accordance with such subsection, make any payment required under such subsection with respect to such drug; and

“(6) the manufacturer complies with require-
ments imposed by the Secretary for purposes of ad-
ministering the program, including with respect to
the duties described in section 1196.

“(b) Agreement in Effect Until Drug Is No
Longer a Selected Drug.—An agreement entered into
under this section shall be effective, with respect to a drug,
until such drug is no longer considered a selected drug
under section 1192(c).

“(c) Special Rule for Certain Selected Drugs
Without AIM Price.—

“(1) In general.—In the case of a selected
drug for which there is no AIM price available with
respect to the initial price applicability year for such
drug and for which an AIM price becomes available
beginning with respect to a subsequent plan year
during the price applicability period for such drug,
if the Secretary determines that the amount de-
scribed in paragraph (2)(A) for such drug is greater
than the amount described in paragraph (2)(B) for
such drug, then by not later than one year after the
date of such determination, the manufacturer of
such selected drug shall pay to the Treasury an amount equal to the difference between such amount described in paragraph (2)(A) for such drug and such amount described in paragraph (2)(B) for such drug.

“(2) AMOUNTS DESCRIBED.—

“(A) WEIGHTED AVERAGE PRICE BEFORE AIM PRICE AVAILABLE.—For purposes of paragraph (1), the amount described in this subparagraph for a selected drug described in such paragraph, is the amount equal to the weighted average manufacturer price for such dosage strength and form for the drug during the period beginning with the first plan year for which the drug is included on the list of negotiation-eligible drugs published under section 1192(d) and ending with the last plan year during the price applicability period for such drug with respect to which there is no AIM price available for such drug.

“(B) AMOUNT MULTIPLIER AFTER AIM PRICE AVAILABLE.—For purposes of paragraph (1), the amount described in this subparagraph for a selected drug described in such paragraph, is the amount equal to 200 percent of the AIM
price for such drug with respect to the first
plan year during the price applicability period
for such drug with respect to which there is an
AIM price available for such drug.

“(d) CONFIDENTIALITY OF INFORMATION.—Infor-
mation submitted to the Secretary under this part by a
manufacturer of a selected drug that is proprietary infor-
mation of such manufacturer (as determined by the Sec-
retary) may be used only by the Secretary or disclosed
to and used by the Comptroller General of the United
States or the Medicare Payment Advisory Commission for
purposes of carrying out this part.

“(e) REGULATIONS.—

“(1) IN GENERAL.—The Secretary shall, pursu-
ant to rulemaking, specify, in accordance with para-
graph (2), the information that must be submitted
under subsection (a)(4).

“(2) INFORMATION SPECIFIED.—Information
described in paragraph (1), with respect to a se-
lected drug, shall include information on sales of the
drug (by the manufacturer of the drug or by another
entity under license or other agreement with the
manufacturer, with respect to the sales of such drug,
regardless of the name under which the drug is sold)
in any foreign country that is part of the AIM price.
The Secretary shall verify, to the extent practicable, such sales from appropriate officials of the government of the foreign country involved.

“(f) Compliance With Requirements for Administration of Program.—Each manufacturer with an agreement in effect under this section shall comply with requirements imposed by the Secretary or a third party with a contract under section 1196(c)(1), as applicable, for purposes of administering the program.

“SEC. 1194. NEGOTIATION AND RENEGOTIATION PROCESS.

“(a) In General.—For purposes of this part, under an agreement under section 1193 between the Secretary and a manufacturer of a selected drug, with respect to the period for which such agreement is in effect and in accordance with subsections (b) and (c), the Secretary and the manufacturer—

“(1) shall during the voluntary negotiation period with respect to the initial price applicability year for such drug, in accordance with this section, negotiate a maximum fair price for such drug for the purpose described in section 1193(a)(1); and

“(2) as applicable pursuant to section 1193(a)(2) and in accordance with the process specified pursuant to such section, renegotiate such max-
imum fair price for such drug for the purpose described in such section.

“(b) Negotiating Methodology and Objective.—

“(1) In general.—The Secretary shall develop and use a consistent methodology for negotiations under subsection (a) that, in accordance with paragraph (2) and subject to paragraph (3), achieves the lowest maximum fair price for each selected drug while appropriately rewarding innovation.

“(2) Prioritizing factors.—In considering the factors described in subsection (d) in negotiating (and, as applicable, renegotiating) the maximum fair price for a selected drug, the Secretary shall, to the extent practicable, consider all of the available factors listed but shall prioritize the following factors:

“(A) Research and development costs.—The factor described in paragraph (1)(A) of subsection (d).

“(B) Market data.—The factor described in paragraph (1)(B) of such subsection.

“(C) Unit costs of production and distribution.—The factor described in paragraph (1)(C) of such subsection.
“(D) COMPARISON TO EXISTING THERAPEUTIC ALTERNATIVES.—The factor described in paragraph (2)(A) of such subsection.

“(3) REQUIREMENT.—

“(A) IN GENERAL.—In negotiating the maximum fair price of a selected drug, with respect to an initial price applicability year for the selected drug, and, as applicable, in renegotiating the maximum fair price for such drug, with respect to a subsequent year during the price applicability period for such drug, in the case that the manufacturer of the selected drug offers under the negotiation or renegotiation, as applicable, a price for such drug that is not more than the target price described in subparagraph (B) for such drug for the respective year, the Secretary shall agree under such negotiation or renegotiation, respectively, to such offered price as the maximum fair price.

“(B) TARGET PRICE.—

“(i) IN GENERAL.—Subject to clause (ii), the target price described in this subparagraph for a selected drug with respect to a year, is the average price (which shall be the net average price, if practicable, and
volume-weighted, if practicable) for any
dosage form and strength of a unit for the
drug for sales of such drug, as computed
in the applicable country described in sec-
tion 1191(c)(3)(B) with respect to such
drug that, with respect to such year, has
the lowest average price for such drug as
compared to the average prices (as so com-
puted) for such drug with respect to such
year in the other applicable countries de-
scribed in such section with respect to such
drug.

“(ii) SELECTED DRUGS WITHOUT AIM
PRICE.—In applying this paragraph in the
case of negotiating the maximum fair price
of a selected drug for which there is no
AIM price available with respect to the ini-
tial price applicability year for such drug,
or, as applicable, renegotiating the max-
imum fair price for such drug with respect
to a subsequent year during the price ap-
plicability period for such drug before the
first plan year for which there is an AIM
price available for such drug, the target
price described in this subparagraph for
such drug and respective year is the
amount that is 80 percent of the average
manufacturer price for such drug and
year.

“(4) Annual report.—After the completion
of each voluntary negotiation period, the Secretary
shall submit to Congress a report on the maximum
fair prices negotiated (or, as applicable, renegoti-
ated) for such period. Such report shall include in-
formation on how such prices so negotiated (or re-
egotiated) meet the requirements of this part, in-
cluding the requirements of this subsection.

“(c) Limitation.—

“(1) In general.—Subject to paragraph (2),
the maximum fair price negotiated (including as re-
egotiated) under this section for a selected drug,
with respect to each plan year during a price appli-
cability period for such drug, shall not exceed 120
percent of the AIM price applicable to such drug
with respect to such year.

“(2) Selected drugs without AIM price.—
In the case of a selected drug for which there is no
AIM price available with respect to the initial price
applicability year for such drug, for each plan year
during the price applicability period before the first
plan year for which there is an AIM price available for such drug, the maximum fair price negotiated (including as renegotiated) under this section for the selected drug shall not exceed the amount equal to 85 percent of the average manufacturer price for the drug with respect to such year.

“(d) CONSIDERATIONS.—For purposes of negotiating and, as applicable, renegotiating (including for purposes of determining whether to renegotiate) the maximum fair price of a selected drug under this part with the manufacturer of the drug, the Secretary shall, consistent with subsection (b)(2), take into consideration the following factors:

“(1) MANUFACTURER-SPECIFIC INFORMATION.—The following information, including as submitted by the manufacturer:

“(A) Research and development costs of the manufacturer for the drug and the extent to which the manufacturer has recouped research and development costs.

“(B) Market data for the drug, including the distribution of sales across different programs and purchasers and projected future revenues for the drug.
“(C) Unit costs of production and distribution of the drug.

“(D) Prior Federal financial support for novel therapeutic discovery and development with respect to the drug.

“(E) Data on patent and on existing and pending exclusivity for the drug.

“(F) National sales data for the drug.

“(G) Information on clinical trials for the drug in the United States or in applicable countries described in section 1191(c)(3)(B).

“(2) INFORMATION ON ALTERNATIVE PRODUCTS.—The following information:

“(A) The extent to which the drug represents a therapeutic advance as compared to existing therapeutic alternatives and, to the extent such information is available, the costs of such existing therapeutic alternatives.

“(B) Information on approval by the Food and Drug Administration of alternative drug products.

“(C) Information on comparative effectiveness analysis for such products.

“(3) FOREIGN SALES INFORMATION.—To the extent available on a timely basis, including as pro-
vided by a manufacturer of the selected drug or otherwise, information on sales of the selected drug in each of the countries described in section 1191(e)(3)(B).

“(4) ADDITIONAL INFORMATION.—Information submitted to the Secretary, in accordance with a process specified by the Secretary, by other parties that are affected by the establishment of a maximum fair price for the selected drug.

“(e) REQUEST FOR INFORMATION.—For purposes of negotiating and, as applicable, renegotiating (including for purposes of determining whether to renegotiate) the maximum fair price of a selected drug under this part with the manufacturer of the drug, with respect to a price applicability period, and other relevant data for purposes of this section—

“(1) the Secretary shall, not later than the selected drug publication date with respect to the initial price applicability year of such period, request drug pricing information from the manufacturer of such selected drug, including information described in subsection (d)(1); and

“(2) by not later than October 1 following the selected drug publication date, the manufacturer of such selected drug shall submit to the Secretary
such requested information in such form and manner as the Secretary may require.

The Secretary shall request, from the manufacturer or others, such additional information as may be needed to carry out the negotiation and renegotiation process under this section.

“SEC. 1195. PUBLICATION OF MAXIMUM FAIR PRICES.

“(a) In General.—With respect to an initial price applicability year and selected drug with respect to such year, not later than May 1 of the plan year prior to such initial price applicability year, the Secretary shall publish in the Federal Register the maximum fair price negotiated under this part with the manufacturer of such drug.

“(b) Updates.—

“(1) Subsequent year maximum fair prices.—For a selected drug, for each plan year subsequent to the initial price applicability year for such drug with respect to which an agreement for such drug is in effect under section 1193, the Secretary shall publish in the Federal Register—

“(A) subject to subparagraph (B), the amount equal to the maximum fair price published for such drug for the previous year, increased by the annual percentage increase in the consumer price index for all urban con-
sumers (all items; U.S. city average) as of Sep-
tember of such previous year; or

“(B) in the case the maximum fair price
for such drug was renegotiated, for the first
year for which such price as so renegotiated ap-
plies, such renegotiated maximum fair price.

“(2) Prices negotiated after deadline.—
In the case of a selected drug with respect to an ini-
tial price applicability year for which the maximum
fair price is determined under this part after the
date of publication under this section, the Secretary
shall publish such maximum fair price in the Fed-
eral Register by not later than 30 days after the
date such maximum price is so determined.

“SEC. 1196. ADMINISTRATIVE DUTIES; COORDINATION PRO-
VISIONS.

“(a) Administrative Duties.—

“(1) In general.—For purposes of section
1191, the administrative duties described in this sec-
tion are the following:

“(A) The establishment of procedures (in-
cluding through agreements with manufacturers
under this part, contracts with prescription
drug plans under part D of title XVIII and
MA–PD plans under part C of such title, and
agreements under section 1197 with group
health plans and health insurance issuers of
health insurance coverage offered in the indi-
vidual or group market) under which the max-
imum fair price for a selected drug is provided
to fair price eligible individuals described in
subparagraph (A) or (B) of section 1191(c)(1)
at pharmacies or by mail order service at the
point-of-sale of the drug for the applicable price
period for such drug and providing that such
maximum fair price is used for determining
cost-sharing under such plans or coverage for
the selected drug.

“(B) The establishment of procedures (in-
cluding through agreements with manufacturers
under this part and contracts with hospitals,
physicians, and other providers of services and
suppliers) under which, in the case of a selected
drug administered by such a hospital, physician,
or other provider of services or supplier to fair
price eligible individuals described in subpara-
graph (C) of section 1191(c)(1) and if payment
for such drug may be made under part A of
title XVIII or part B of such title, the max-
imum fair price for the selected drug is pro-
vided to such hospitals, physicians, and other
providers of services and suppliers (as applica-
ble) and providing that such maximum fair
price is used for determining cost-sharing under
the respective part, for the selected drug.

“(C) The establishment of procedures (in-
cluding through agreements and contracts de-
scribed in subparagraphs (A) and (B)) to en-
sure that, not later than 90 days after the dis-
pensing of a selected drug to a fair price eligi-
ble individual by a pharmacy or mail order serv-
vice, the pharmacy or mail order service is reim-
bursed for an amount equal to the difference
between—

“(i) the lesser of—

“(I) the wholesale acquisition
cost of the drug;

“(II) the national average drug
acquisition cost of the drug; and

“(III) any other similar deter-
mination of pharmacy acquisition
costs of the drug, as determined by
the Secretary; and

“(ii) the maximum fair price for the
drug.
“(D) The establishment of procedures to ensure that the maximum fair price for a selected drug is applied before—

“(i) any coverage or financial assistance under other health benefit plans or programs that provide coverage or financial assistance for the purchase or provision of prescription drug coverage on behalf of fair price eligible individuals as the Secretary may specify; and

“(ii) any other discounts.

“(E) The establishment of procedures to enter into appropriate agreements and protocols for the ongoing computation of AIM prices for selected drugs, including, to the extent possible, to compute the AIM price for selected drugs and including by providing that the manufacturer of such a selected drug should provide information for such computation not later than 3 months after the first date of the voluntary negotiation period for such selected drug.

“(F) The establishment of procedures to compute and apply the maximum fair price across different strengths and dosage forms of a selected drug that are not based on the spe-
specific formulation, dosage or strength, packaging, or form of administration.

“(G) The establishment of procedures to negotiate and apply the maximum fair price in a manner that does not include any dispensing or similar fee.

“(H) The establishment of procedures to carry out the provisions of this part with respect to—

“(i) fair price eligible individuals who are enrolled under a prescription drug plan under part D of title XVIII or an MA–PD plan under part C of such title; and

“(ii) fair price eligible individuals who are enrolled under a group health plan or health insurance coverage offered by a health insurance issuer in the individual or group market with respect to which there is an agreement in effect under section 1197.

“(I) The establishment of a negotiation process and renegotiation process in accordance with section 1194, including a process for acquiring information described in subsection (d)
of such section and determining amounts described in subsection (b) of such section.

“(J) The provision of a reasonable dispute resolution mechanism to resolve disagreements between manufacturers, fair price eligible individuals, and the third party with a contract under subsection (e)(1).

“(2) MONITORING COMPLIANCE.—

“(A) IN GENERAL.—The Secretary shall monitor compliance by a manufacturer with the terms of an agreement under section 1193, including by establishing a mechanism through which violations of such terms may be reported.

“(B) NOTIFICATION.—If a third party with a contract under subsection (e)(1) determines that the manufacturer is not in compliance with such agreement, the third party shall notify the Secretary of such nonecompliance for appropriate enforcement under section 4192 of the Internal Revenue Code of 1986 or section 1198, as applicable.

“(b) COLLECTION OF DATA.—

“(1) FROM PRESCRIPTION DRUG PLANS AND MA–PD PLANS.—The Secretary may collect appropriate data from prescription drug plans under part
D of title XVIII and MA–PD plans under part C of such title in a timeframe that allows for maximum fair prices to be provided under this part for selected drugs.

“(2) FROM HEALTH PLANS.—The Secretary may collect appropriate data from group health plans or health insurance issuers offering group or individual health insurance coverage in a timeframe that allows for maximum fair prices to be provided under this part for selected drugs.

“(c) CONTRACT WITH THIRD PARTIES.—

“(1) IN GENERAL.—The Secretary shall enter into a contract with 1 or more third parties to administer the requirements established by the Secretary in order to carry out this part. At a minimum, the contract with a third party under the preceding sentence shall require that the third party—

“(A) receive and transmit information between the Secretary, manufacturers, and other individuals or entities the Secretary determines appropriate;

“(B) receive, distribute, or facilitate the distribution of funds of manufacturers to appropriate individuals or entities in order to
meet the obligations of manufacturers under agreements under this part;

“(C) provide adequate and timely information to manufacturers, consistent with the agreement with the manufacturer under this part, as necessary for the manufacturer to fulfill its obligations under this part; and

“(D) permit manufacturers to conduct periodic audits, directly or through contracts, of the data and information used by the third party to determine discounts for applicable drugs of the manufacturer under the program.

“(2) PERFORMANCE REQUIREMENTS.—The Secretary shall establish performance requirements for a third party with a contract under paragraph (1) and safeguards to protect the independence and integrity of the activities carried out by the third party under the program under this part.

“(d) COORDINATION WITH 340B PROGRAM.—In the case of a manufacturer of a selected drug, with respect to an initial price applicability year, for each year with respect to which a maximum fair price is applied under this part for such drug, such drug shall not be considered a covered outpatient drug subject to an agreement under section 340B of the Public Health Service Act.
“SEC. 1197. VOLUNTARY PARTICIPATION BY OTHER HEALTH PLANS.

“(a) IN GENERAL.—Under the program under this part the Secretary shall be treated as having in effect an agreement with a group health plan or health insurance issuer offering health insurance coverage (as such terms are defined in section 2791 of the Public Health Service Act), except in the case that such a plan or issuer affirmatively elects not to participate under the program, through a process specified by the Secretary, with respect to a price applicability period and a selected drug with respect to such period with respect to which coverage is provided under such plan or coverage.

“(b) PUBLICATION OF ELECTION.—With respect to each price applicability period and each selected drug with respect to such period, the Secretary and the Secretary of Labor and the Secretary of the Treasury, as applicable, shall make public a list of each group health plan and each issuer of health insurance coverage, with respect to which coverage is provided under such plan or coverage for such drug, that has elected under subsection (a) not to participate under the program with respect to such period and drug.

“SEC. 1198. CIVIL MONETARY PENALTY.

“(a) VIOLATIONS RELATING TO OFFERING OF MAXIMUM FAIR PRICE.—Any manufacturer of a selected drug
that has entered into an agreement under section 1193, with respect to a plan year during the price applicability period for such drug, that does not provide access to a price that is not more than the maximum fair price (or a lesser price) for such drug for such year—

“(1) to a fair price eligible individual described in subparagraph (A) or (B) of section 1191(c)(1) furnished such drug during such year; or

“(2) to a hospital, physician, or other provider of services or supplier with respect to fair price eligible individuals described in subparagraph (C) of such section administered such drug during such year;

shall be subject to a civil monetary penalty equal to ten times the amount equal to the difference between the price for such drug made available by such manufacturer with respect to such individual or hospital, physician, provider, or supplier and the maximum fair price for such drug for such year.

“(b) Violations of Certain Terms of Agreement.—Any manufacturer of a selected drug that has entered into an agreement under section 1193, with respect to a plan year during the price applicability period for such drug, that is in violation of a requirement imposed pursuant to section 1193(a)(6) shall be subject to a civil
monetary penalty of not more than $1,000,000 for each such violation.

“(c) APPLICATION.—The provisions of section 1128A (other than subsections (a) and (b)) shall apply to a civil monetary penalty under this section in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a).

“SEC. 1199. MISCELLANEOUS PROVISIONS.

“(a) PAPERWORK REDUCTION ACT.—Chapter 35 of title 44, United States Code, shall not apply to data collected under this part.

“(b) NATIONAL ACADEMY OF MEDICINE STUDY.—Not later than December 31, 2025, the National Academy of Medicine shall conduct a study, and submit to Congress a report, on recommendations for improvements to the program under this part, including the determination of the limits applied under section 1194(c).

“(c) MEDPAC STUDY.—Not later than December 31, 2025, the Medicare Payment Advisory Commission shall conduct a study, and submit to Congress a report, on the program under this part with respect to the Medicare program under title XVIII, including with respect to the effect of the program on individuals entitled to benefits or enrolled under such title.
“(d) Limitation on Judicial Review.—The following shall not be subject to judicial review:

“(1) The selection of drugs for publication under section 1192(a).

“(2) The determination of whether a drug is a negotiation-eligible drug under section 1192(d).

“(3) The determination of the maximum fair price of a selected drug under section 1194.

“(4) The determination of units of a drug for purposes of section 1191(c)(3).

“(e) Coordination.—In carrying out this part with respect to group health plans or health insurance coverage offered in the group market that are subject to oversight by the Secretary of Labor or the Secretary of the Treasury, the Secretary of Health and Human Services shall coordinate with such respective Secretary.

“(f) Data Sharing.—The Secretary shall share with the Secretary of the Treasury such information as is necessary to determine the tax imposed by section 4192 of the Internal Revenue Code of 1986.”.

(b) Application of Maximum Fair Prices and Conforming Amendments.—

(1) Under Medicare Prescription Drug Program.—
(A) Exception to non-interference.—Section 1860D–11(i) of the Social Security Act (42 U.S.C. 1395w–111(i)) is amended by inserting “, except as provided under part E of title XI,” after “the Secretary”.

(B) Application as negotiated price.—Section 1860D–2(d)(1) of the Social Security Act (42 U.S.C. 1395w–102(d)(1)) is amended—

(i) in subparagraph (B), by inserting “, subject to subparagraph (D),” after “negotiated prices”; and

(ii) by adding at the end the following new subparagraph:

“(D) Application of maximum fair price for selected drugs.—In applying this section, in the case of a covered part D drug that is a selected drug (as defined in section 1192(c)), with respect to a price applicability period (as defined in section 1191(b)(2)), the negotiated price described in this subsection shall be the maximum fair price (as defined in section 1191(c)(2)) for such drug and for each plan year during such period.”.
(C) INFORMATION FROM PRESCRIPTION DRUG PLANS AND MA–PD PLANS REQUIRED.—

(i) PRESCRIPTION DRUG PLANS.—Section 1860D–12(b) of the Social Security Act (42 U.S.C. 1395w–112(b)) is amended by adding at the end the following new paragraph:

“(8) Provision of information related to maximum fair prices.—Each contract entered into with a PDP sponsor under this part with respect to a prescription drug plan offered by such sponsor shall require the sponsor to provide information to the Secretary as requested by the Secretary in accordance with section 1196(b).”.

(ii) MA–PD PLANS.—Section 1857(f)(3) of the Social Security Act (42 U.S.C. 1395w–27(f)(3)) is amended by adding at the end the following new sub-

paragraph:

“(E) Provision of information related to maximum fair prices.—Section 1860D–12(b)(8).”.

(2) UNDER GROUP HEALTH PLANS AND HEALTH INSURANCE COVERAGE.—
(A) PHSA.—Part A of title XXVII of the Public Health Service Act is amended by insert-
ing after section 2729 the following new sec-
tion:

“SEC. 2729A. FAIR PRICE DRUG NEGOTIATION PROGRAM AND APPLICATION OF MAXIMUM FAIR PRICES.

“(a) IN GENERAL.—In the case of a group health plan or health insurance issuer offering health insurance coverage that is treated under section 1197 of the Social Security Act as having in effect an agreement with the Secretary under the Fair Price Drug Negotiation Program under part E of title XI of such Act, with respect to a price applicability period (as defined in section 1191(b) of such Act) and a selected drug (as defined in section 1192(c) of such Act) with respect to such period with re-
spect to which coverage is provided under such plan or coverage—

“(1) the provisions of such part shall apply to the plans or coverage offered by such plan or issuer, and to the individuals enrolled under such plans or coverage, during such period, with respect to such selected drug, in the same manner as such provi-
sions apply to prescription drug plans and MA–PD
plans, and to individuals enrolled under such pre-
scription drug plans and MA–PD plans;

“(2) the plan or issuer shall apply any cost-
sharing responsibilities under such plan or coverage,
with respect to such selected drug, by substituting
the maximum fair price negotiated under such part
for such drug in lieu of the contracted rate under
such plan or coverage for such selected drug; and

“(3) the Secretary shall apply the provisions of
such part to such plan, issuer, and coverage, and
such individuals so enrolled in such plans.

“(b) Notification Regarding Nonparticipation
in Fair Drug Price Negotiation Program.—A group
health plan or a health insurance issuer offering group or
individual health insurance coverage shall publicly disclose
in a manner and in accordance with a process specified
by the Secretary any election made under section 1197
of the Social Security Act by the plan or issuer to not
participate in the Fair Drug Price Negotiation Program
under part E of title XI of such Act with respect to a
selected drug (as defined in section 1192(c) of such Act)
for which coverage is provided under such plan or coverage
before the beginning of the plan year for which such elec-
tion was made.”.

(B) ERISA.—
(i) **IN GENERAL.**—Subpart B of part 7 of subtitle B of title I of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1181 et. seq.) is amended by adding at the end the following new section:

```
“SEC. 716. FAIR PRICE DRUG NEGOTIATION PROGRAM AND APPLICATION OF MAXIMUM FAIR PRICES.

“(a) **IN GENERAL.**—In the case of a group health plan or health insurance issuer offering group health insurance coverage that is treated under section 1197 of the Social Security Act as having in effect an agreement with the Secretary under the Fair Price Drug Negotiation Program under part E of title XI of such Act, with respect to a price applicability period (as defined in section 1191(b) of such Act) and a selected drug (as defined in section 1192(c) of such Act) with respect to such period, with respect to which coverage is provided under such plan or coverage—

“(1) the provisions of such part shall apply to the plans or coverage offered by such plan or issuer, and to the individuals enrolled under such plans or coverage, during such period, with respect to such selected drug, in the same manner as such provisions apply to prescription drug plans and MA–PD
```
plans, and to individuals enrolled under such pre-
scription drug plans and MA–PD plans;

“(2) the plan or issuer shall apply any cost-
sharing responsibilities under such plan or coverage,
with respect to such selected drug, by substituting
the maximum fair price negotiated under such part
for such drug in lieu of the contracted rate under
such plan or coverage for such selected drug; and

“(3) the Secretary shall apply the provisions of
such part to such plan, issuer, and coverage, and
such individuals so enrolled in such plans.

“(b) Notification Regarding Nonparticipation
in Fair Drug Price Negotiation Program.—A group
health plan or a health insurance issuer offering group
health insurance coverage shall publicly disclose in a man-
ner and in accordance with a process specified by the Sec-
retary any election made under section 1197 of the Social
Security Act by the plan or issuer to not participate in
the Fair Drug Price Negotiation Program under part E
of title XI of such Act with respect to a selected drug (as
defined in section 1192(e) of such Act) for which coverage
is provided under such plan or coverage before the begin-
ing of the plan year for which such election was made.”.

(ii) Clerical Amendment.—The
table of sections for part 7 of subtitle B of
title I of the Employee Retirement Income
Security Act of 1974 is amended by adding
at the end the following:

“(Sec. 716. Fair Price Drug Negotiation Program and application of maximum
fair prices.”).

(C) IRC.—

(i) IN GENERAL.—Subchapter B of
chapter 100 of the Internal Revenue Code
of 1986 is amended by adding at the end
the following new section:

“SEC. 9816. FAIR PRICE DRUG NEGOTIATION PROGRAM
AND APPLICATION OF MAXIMUM FAIR
PRICES.

“(a) IN GENERAL.—In the case of a group health
plan that is treated under section 1197 of the Social Secu-
rity Act as having in effect an agreement with the Sec-
retary under the Fair Price Drug Negotiation Program
under part E of title XI of such Act, with respect to a
price applicability period (as defined in section 1191(b)
of such Act) and a selected drug (as defined in section
1192(c) of such Act) with respect to such period with re-
spect to which coverage is provided under such plan—

“(1) the provisions of such part shall apply to
the plans offered by such plan, and to the individ-
uals enrolled under such plans, during such period,
with respect to such selected drug, in the same man-
• HR 3 IH

n as such provisions apply to prescription drug
plans and MA–PD plans, and to individuals enrolled
under such prescription drug plans and MA–PD
plans;

“(2) the plan shall apply any cost-sharing re-
sponsibilities under such plan, with respect to such
selected drug, by substituting the maximum fair
price negotiated under such part for such drug in
lieu of the contracted rate under such plan for such
selected drug; and

“(3) the Secretary shall apply the provisions of
such part to such plan and such individuals so en-
rolled in such plan.

“(b) Notification Regarding Nonparticipation
In Fair Drug Price Negotiation Program.—A group
health plan shall publicly disclose in a manner and in ac-
cordance with a process specified by the Secretary any
election made under section 1197 of the Social Security
Act by the plan to not participate in the Fair Drug Price
Negotiation Program under part E of title XI of such Act
with respect to a selected drug (as defined in section
1192(c) of such Act) for which coverage is provided under
such plan before the beginning of the plan year for which
such election was made.”.
(ii) Clerical Amendment.—The table of sections for subchapter B of chapter 100 of such Code is amended by adding at the end the following new item:

“Sec. 9816. Fair Price Drug Negotiation Program and application of maximum fair prices.”.

SEC. 102. SELECTED DRUG MANUFACTURER EXCISE TAX IMPOSED DURING NONCOMPLIANCE PERIODS.

(a) In General.—Subchapter E of chapter 32 of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:

“SEC. 4192. SELECTED DRUGS DURING NONCOMPLIANCE PERIODS.

“(a) In General.—There is hereby imposed on the sale by the manufacturer, producer, or importer of any selected drug during a day described in subsection (b) a tax in an amount such that the applicable percentage is equal to the ratio of—

“(1) such tax, divided by

“(2) the sum of such tax and the price for which so sold.

“(b) Noncompliance Periods.—A day is described in this subsection with respect to a selected drug if it is a day during one of the following periods:
“(1) The period beginning on the June 16th immediately following the selected drug publication date and ending on the first date during which the manufacturer of the drug has in place an agreement described in subsection (a) of section 1193 of the Social Security Act with respect to such drug.

“(2) The period beginning on the April 1st immediately following the June 16th described in paragraph (1) and ending on the first date during which the manufacturer of the drug has agreed to a maximum fair price under such agreement.

“(3) In the case of a selected drug with respect to which the Secretary of Health and Human Services has specified a renegotiation period under such agreement, the period beginning on the first date after the last date of such renegotiation period and ending on the first date during which the manufacturer of the drug has agreed to a renegotiated maximum fair price under such agreement.

“(4) With respect to information that is required to be submitted to the Secretary of Health and Human Services under such agreement, the period beginning on the date on which such Secretary certifies that such information is overdue and ending on the date that such information is so submitted.
“(5) In the case of a selected drug with respect to which a payment is due under subsection (c) of such section 1193, the period beginning on the date on which the Secretary of Health and Human Services certifies that such payment is overdue and ending on the date that such payment is made in full.

“(c) APPLICABLE PERCENTAGE.—The term ‘applicable percentage’ means—

“(1) in the case of sales of a selected drug during the first 90 days described in subsection (b) with respect to such drug, 65 percent,

“(2) in the case of sales of such drug during the 91st day through the 180th day described in subsection (b) with respect to such drug, 75 percent,

“(3) in the case of sales of such drug during the 181st day through the 270th day described in subsection (b) with respect to such drug, 85 percent, and

“(4) in the case of sales of such drug during any subsequent day, 95 percent.

“(d) DEFINITIONS.—The terms ‘selected drug publication date’ and ‘maximum fair price’ have the meaning given such terms in section 1191 of the Social Security Act and the term ‘selected drug’ has the meaning given such term in section 1192 of such Act.
“(e) Anti-Abuse Rule.—In the case of a sale which was timed for the purpose of avoiding the tax imposed by this section, the Secretary may treat such sale as occurring during a day described in subsection (b).”.

(b) No Deduction for Excise Tax Payments.— Section 275 of the Internal Revenue Code of 1986 is amended by adding “or by section 4192” before the period at the end of subsection (a)(6).

(e) Conforming Amendments.—

(1) Section 4221(a) of the Internal Revenue Code of 1986 is amended by inserting “or 4192” after “section 4191”.

(2) Section 6416(b)(2) of such Code is amended by inserting “or 4192” after “section 4191”.

(d) Clerical Amendments.—

(1) The heading of subchapter E of chapter 32 of the Internal Revenue Code of 1986 is amended by striking “Medical Devices” and inserting “Other Medical Products”.

(2) The table of subchapters for chapter 32 of such Code is amended by striking the item relating to subchapter E and inserting the following new item:

“SUBCHAPTER E. OTHER MEDICAL PRODUCTS”.

“HR 3 IH
(3) The table of sections for subchapter E of chapter 32 of such Code is amended by adding at the end the following new item:

“Sec. 4192. Selected drugs during noncompliance periods.”.

(e) Effective Date.—The amendments made by this section shall apply to sales after the date of the enactment of this Act.

TITLE II—MEDICARE PARTS B AND D PRESCRIPTION DRUG INFLATION REBATES

SEC. 201. MEDICARE PART B REBATE BY MANUFACTURERS.

(a) In General.—Section 1834 of the Social Security Act (42 U.S.C. 1395m) is amended by adding at the end the following new subsection:

“(x) Rebate by Manufacturers for Single Source Drugs With Prices Increasing Faster Than Inflation.—

“(1) Requirements.—

“(A) Secretarial provision of information.—Not later than 6 months after the end of each calendar quarter beginning on or after July 1, 2021, the Secretary shall, for each part B rebatable drug, report to each manufacturer of such part B rebatable drug the following for such calendar quarter:
“(i) Information on the total number of billing units described in subparagraph (A)(i) of paragraph (3) with respect to such drug and calendar quarter.

“(ii) Information on the amount (if any) of the excess average sales price increase described in subparagraph (A)(ii) of such paragraph for such drug and calendar quarter.

“(iii) The rebate amount specified under such paragraph for such part B rebatable drug and calendar quarter.

“(B) Manufacturer Requirement.—For each calendar quarter beginning on or after July 1, 2021, the manufacturer of a part B rebatable drug shall, for such drug, not later than 30 days after the date of receipt from the Secretary of the information described in subparagraph (A) for such calendar quarter, provide to the Secretary a rebate that is equal to the amount specified in paragraph (3) for such drug for such calendar quarter.

“(2) Part B Rebatable Drug Defined.—

“(A) In General.—In this subsection, the term ‘part B rebatable drug’ means a single
source drug or biological (as defined in subparagraph (D) of section 1847A(c)(6)), including a biosimilar biological product (as defined in subparagraph (H) of such section), paid for under this part, except such term shall not include such a drug or biological—

“(i) if the average total allowed charges for a year per individual that uses such a drug or biological, as determined by the Secretary, are less than, subject to subparagraph (B), $100; or

“(ii) that is a vaccine described in subparagraph (A) or (B) of section 1861(s)(10).

“(B) INCREASE.—The dollar amount applied under subparagraph (A)(i)—

“(i) for 2022, shall be the dollar amount specified under such subparagraph for 2021, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) as of the first quarter of the previous year; and

“(ii) for a subsequent year, shall be the dollar amount specified in this clause
(or clause (i)) for the previous year, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) as of the first quarter of the previous year. Any dollar amount specified under this subparagraph that is not a multiple of $10 shall be rounded to the nearest multiple of $10.

“(3) Rebate amount.—

“(A) In general.—For purposes of paragraph (1)(B), the amount specified in this paragraph for a part B rebatable drug assigned to a billing and payment code for a calendar quarter is, subject to paragraph (4), the amount equal to the product of—

“(i) subject to subparagraph (B), the total number of billing units, as described in section 1847A(b)(6)(B), for such part B rebatable drug furnished under this part during the calendar quarter; and

“(ii) the amount (if any) by which—

“(I) the payment amount under subparagraph (B) or (C) of section 1847A(b)(1), as applicable, for such
part B rebatable drug during the calendar quarter; exceeds

“(II) the inflation-adjusted payment amount determined under subparagraph (C) for such part B rebatable drug during the calendar quarter.

“(B) EXCLUDED UNITS.—For purposes of subparagraph (A)(i), the total number of billing units for part B rebatable drugs furnished during a calendar quarter shall not include—

“(i) units packaged into the payment for a related procedure or service under section 1833(t) or under section 1833(i) (instead of separately payable under such respective section);

“(ii) units included under the single payment system for renal dialysis services under section 1881(b)(14); or

“(iii) units of a part B rebatable drug of a manufacturer that is furnished to an individual, if such manufacturer, with respect to the furnishing of such units of such drug, provides for discounts under
section 340B of the Public Health Service Act or for rebates under section 1927.

“(C) **Determination of inflation-adjusted payment amount.**—The inflation-adjusted payment amount determined under this subparagraph for a part B rebatable drug for a calendar quarter is—

“(i) the payment amount for the billing and payment code for such drug in the payment amount benchmark quarter (as defined in subparagraph (D)); increased by

“(ii) the percentage by which the rebate period CPI–U (as defined in subparagraph (F)) for the calendar quarter exceeds the benchmark period CPI–U (as defined in subparagraph (E)).

“(D) **Payment amount benchmark quarter.**—The term ‘payment amount benchmark quarter’ means the calendar quarter beginning January 1, 2016.

“(E) **Benchmark period CPI–U.**—The term ‘benchmark period CPI–U’ means the consumer price index for all urban consumers (United States city average) for July 2015.
“(F) Rebate period CPI–U.—The term ‘rebate period CPI–U’ means, with respect to a calendar quarter described in subparagraph (C), the greater of the benchmark period CPI–U and the consumer price index for all urban consumers (United States city average) for the first month of the calendar quarter that is two calendar quarters prior to such described calendar quarter.

“(4) Special treatment of certain drugs and exemption.—

“(A) Subsequently approved drugs.— Subject to subparagraph (B), in the case of a part B rebatable drug first approved by the Food and Drug Administration after July 1, 2015, clause (i) of paragraph (3)(C) shall be applied as if the term ‘payment amount benchmark quarter’ were defined under paragraph (3)(D) as the third full calendar quarter after the day on which the drug was first marketed and clause (ii) of paragraph (3)(C) shall be applied as if the term ‘benchmark period CPI–U’ were defined under paragraph (3)(E) as if the reference to ‘July 2015’ under such paragraph were a reference to ‘the first month of the first
full calendar quarter after the day on which the
drug was first marketed’.

“(B) TIMELINE FOR PROVISION OF RE-
BATES FOR NEW DRUGS.—In the case of a part
B rebatable drug first approved by the Food
and Drug Administration after July 1, 2015,
clause (i) of paragraph (1)(B) shall be applied
as if the reference to ‘July 1, 2021’ under such
paragraph were a reference to the later of the
6th full calendar quarter after the day on which
the drug was first marketed or July 1, 2021.

“(C) EXEMPTION FOR SHORTAGES.—The
Secretary may reduce or waive the rebate under
paragraph (1)(B) with respect to a part B
rebatable drug that appears on the drug short-
age list in effect under section 506(e) of the
Federal Food, Drug, and Cosmetic Act or in
the case of other exigent circumstances, as de-
termined by the Secretary.

“(D) SELECTED DRUGS.—In the case of a
part B rebatable drug that is a selected drug
(as defined in section 1192(c)), for each appli-
cable year beginning after the price applicability
period (as defined in section 1191(b)(2)) with
respect to such drug, clause (i) of paragraph
(3)(C) shall be applied as if the term ‘payment amount benchmark quarter’ were defined under paragraph (3)(D) as the calendar quarter beginning January 1 of the last year beginning during such price applicability period with respect to such selected drug and clause (ii) of paragraph (3)(C) shall be applied as if the term ‘benchmark period CPI–U’ were defined under paragraph (3)(E) as if the reference to ‘July 2015’ under such paragraph were a reference to the July of the year preceding such last year.

“(5) APPLICATION TO BENEFICIARY COINSURANCE.—In the case of a part B rebatable drug for which a rebate is payable under this subsection—

“(A) in computing the amount of any coinsurance applicable under this title to an individual with respect to such drug, the computation of such coinsurance shall be based on the inflation-adjusted payment amount determined under paragraph (3)(C) for such part B rebatable drug; and

“(B) the amount of such coinsurance is equal to 20 percent of such inflation-adjusted payment amount so determined.
“(6) Rebate deposits.—Amounts paid as rebates under paragraph (1)(B) shall be deposited into the Federal Supplementary Medical Insurance Trust Fund established under section 1841.

“(7) Civil money penalty.—If a manufacturer of a part B rebatable drug has failed to comply with the requirements under paragraph (1)(B) for such drug for a calendar quarter, the manufacturer shall be subject to, in accordance with a process established by the Secretary pursuant to regulations, a civil money penalty in an amount equal to at least 125 percent of the amount specified in paragraph (3) for such drug for such calendar quarter. The provisions of section 1128A (other than subsections (a) (with respect to amounts of penalties or additional assessments) and (b)) shall apply to a civil money penalty under this paragraph in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a).

“(8) Study and report.—

“(A) Study.—The Secretary shall conduct a study of the feasibility of and operational issues involved with the following:
“(i) Including multiple source drugs (as defined in section 1847A(c)(6)(C)) in the rebate system under this subsection.

“(ii) Including drugs and biologicals paid for under MA plans under part C in the rebate system under this subsection.

“(iii) Including drugs excluded under paragraph (2)(A) and billing units of drugs excluded under paragraph (3)(B) in the rebate system under this subsection.

“(B) REPORT.—Not later than 3 years after the date of the enactment of this subsection, the Secretary shall submit to Congress a report on the study conducted under subparagraph (A).

“(9) APPLICATION TO MULTIPLE SOURCE DRUGS.—The Secretary may, based on the report submitted under paragraph (8) and pursuant to rulemaking, apply the provisions of this subsection to multiple source drugs (as defined in section 1847A(c)(6)(C)), including, for purposes of determining the rebate amount under paragraph (3), by calculating manufacturer-specific average sales prices for the benchmark period and the rebate period.”.
(b) Amounts Payable; Cost-Sharing.—Section 1833(a) of the Social Security Act is amended—

(1) in paragraph (1)—

(A) in subparagraph (S), by striking “with respect to” and inserting “subject to subparagraph (DD), with respect to”;

(B) by striking “and (CC)” and inserting “(CC)”;

(C) by inserting before the semicolon at the end the following: “, and (DD) with respect to a part B rebatable drug (as defined in paragraph (2) of section 1834(x)) for which a rebate is payable under such section, the amounts paid shall be the difference between (i) the payment amount under paragraph (3)(A)(ii)(I) of such section for such drug, and (ii) 20 percent of the inflation-adjusted payment amount under paragraph (3)(A)(ii)(II) of such section for such drug”; and

(2) by adding at the end of the flush left matter following paragraph (9), the following:

“For purposes of applying paragraph (1)(DD) and section 1834(x)(5), the Secretary shall make such estimates and use such data as the Secretary determines appropriate.”.
(c) Conforming Amendment to Part B ASP Calculation.—Section 1847A(e)(3) of the Social Security Act (42 U.S.C. 1395w–3a(e)(3)) is amended by inserting “or section 1834(x)” after “section 1927”.

SEC. 202. MEDICARE PART D REBATE BY MANUFACTURERS.

Part D of title XVIII of the Social Security Act is amended by inserting after section 1860D–14A (42 U.S.C. 1395w–114a) the following new section:

“SEC. 1860D–14B. MANUFACTURER REBATE FOR CERTAIN DRUGS WITH PRICES INCREASING FASTER THAN INFLATION.

“(a) In General.—Subject to the provisions of this section, in order for coverage to be available under this part for a part D rebatable drug of a manufacturer dispensed during an applicable year, the manufacturer must have entered into and have in effect an agreement described in subsection (b). For purposes of this section the term ‘applicable year’ means a year beginning with 2022.

“(b) Agreements.—

“(1) Terms of Agreement.—An agreement described in this subsection, with respect to a manufacturer of a part D rebatable drug, is an agreement under which the following applies:

“(A) Secretarial Provision of Information.—Not later than 9 months after the
end of each applicable year with respect to which the agreement is in effect, the Secretary, for the part D rebatable drug of the manufacturer, reports to the manufacturer the following for such year:

“(i) Information on the total units (as defined in subsection (g)(2)) dispensed for each dosage form and strength with respect to such part D rebatable drug and year.

“(ii) Information on the amount (if any) of the excess average manufacturer price increase described in subsection (c)(1)(B) for each dosage form and strength with respect to such drug and year.

“(iii) The rebate amount specified under subsection (c) for each dosage form and strength with respect to such drug and year.

“(B) MANUFACTURER REQUIREMENTS.—For each applicable year with respect to which the agreement is in effect, the manufacturer of the part D rebatable drug, for each dosage form and strength with respect to such drug,
not later than 30 days after the date of receipt from the Secretary of the information described in subparagraph (A) for such year, provides to the Secretary a rebate that is equal to the amount specified in subsection (c) for such dosage form and strength with respect to such drug for such year.

“(2) LENGTH OF AGREEMENT.—

“(A) IN GENERAL.—An agreement under this section, with respect to a part D rebatable drug, shall be effective for an initial period of not less than one year and shall be automatically renewed for a period of not less than one year unless terminated under subparagraph (B).

“(B) TERMINATION.—

“(i) BY SECRETARY.—The Secretary may provide for termination of an agreement under this section for violation of the requirements of the agreement or other good cause shown. Such termination shall not be effective earlier than 60 days after the date of notice of such termination. The Secretary shall provide, upon request, a manufacturer with a hearing concerning
such a termination, but such hearing shall not delay the effective date of the termin-
ination.

“(ii) By a manufacturer.—A man-
ufacturer may terminate an agreement under this section for any reason. Any such termination shall not be effective until the year beginning at least 60 days after the date the manufacturer provides notice to the Secretary.

“(C) Effectiveness of termination.—Any termination under this paragraph shall not affect rebates due under the agreement under this section before the effective date of its ter-
mination.

“(D) Delay before reentry.—In the case of any agreement under this section with a manufacturer which is terminated in a plan year, another such agreement with the manu-
facturer (or a successor manufacturer) may not be entered into before the subsequent plan year, unless the Secretary finds good cause for an earlier reinstatement of such an agreement.

“(3) Information.—For purposes of carrying out this section, the Secretary shall use information
submitted by manufacturers under section 1927(b)(3).

“(c) Rebate Amount.—

“(1) In general.—For purposes of this section, the amount specified in this subsection for a dosage form and strength with respect to a part D rebatable drug and applicable year is, subject to subparagraphs (B) and (C) of paragraph (3), the amount equal to the product of—

“(A) the total average number of units weighted by, and dispensed for, such dosage form and strength with respect to such part D rebatable drug and year; and

“(B) the amount (if any) by which—

“(i) the average manufacturer price (as defined in subsection (g)) paid for such dosage form and strength with respect to such part D rebatable drug during the year; exceeds

“(ii) the inflation-adjusted payment amount determined under paragraph (2) for such dosage form and strength with respect to such part D rebatable drug during the year.
“(2) Determination of Inflation-Adjusted Payment Amount.—The inflation-adjusted payment amount determined under this paragraph for a dosage form and strength with respect to a part D rebatable drug for an applicable year, subject to subparagraphs (A) and (D) of paragraph (3), is—

“(A) the average manufacturer price paid for such dosage form and strength with respect to such drug in the payment amount benchmark year (as defined in subsection (g)(3)); increased by

“(B) the percentage by which the rebate period CPI–U (as defined in subsection (g)(5)) for the applicable year exceeds the benchmark period CPI–U (as defined in subsection (g)(4)).

“(3) Special Treatment of Certain Drugs and Exemption.—

“(A) Subsequently Approved Drugs.—

In the case of a part D rebatable drug first approved by the Food and Drug Administration after January 1, 2016, subparagraph (A) of paragraph (2) shall be applied as if the term ‘payment amount benchmark year’ were defined under subsection (g)(3) as the first year beginning after the day on which the drug was first approved.
marketed and subparagraph (B) of paragraph (2) shall be applied as if the term ‘benchmark period CPI–U’ were defined under subsection (g)(4) as if the reference to ‘January 2016’ under such subsection were a reference to ‘January of the first year beginning after the date on which the drug was first marketed by any manufacturer’.

“(B) EXEMPTION FOR SHORTAGES.—The Secretary may reduce or waive the rebate under paragraph (1) with respect to a part D rebatable drug in the case of a shortage of such drug or other exigent circumstances, as determined by the Secretary.

“(C) TREATMENT OF NEW FORMULATIONS.—

“(i) IN GENERAL.—In the case of a part D rebatable drug that is a line extension of a single source drug or an innovator multiple source drug that is an oral solid dosage form, the Secretary shall establish a formula for determining the amount specified in this subsection with respect to such part D rebatable drug and an applicable year with consideration of
the single source drug or an innovator
multiple source drug.

“(ii) Line extension defined.—In
this subparagraph, the term ‘line exten-
sion’ means, with respect to a part D
rebatable drug, a new formulation of the
drug (as determined by the Secretary),
such as an extended release formulation,
but does not include an abuse-deterrent
formulation of the drug (as determined by
the Secretary), regardless of whether such
abuse-deterrent formulation is an extended
release formulation.

“(D) Selected drugs.—In the case of a
part D rebatable drug that is a selected drug
(as defined in section 1192(c)), for each appli-
cable year beginning after the price applicability
period (as defined in section 1191(b)(2) with
respect to such drug, subparagraph (A) of para-
graph (2) shall be applied as if the term ‘pay-
ment amount benchmark year’ were defined
under subsection (g)(3) as the last year begin-
ning during such price applicability period with
respect to such selected drug and subparagraph
(B) of paragraph (2) shall be applied as if the
term ‘benchmark period CPI–U’ were defined under subsection (g)(4) as if the reference to ‘January 2016’ under such subsection were a reference to January of the last year beginning during such price applicability period with respect to such drug.

“(d) Rebate Deposits.— Amounts paid as rebates under subsection (c) shall be deposited into the Medicare Prescription Drug Account in the Federal Supplementary Medical Insurance Trust Fund established under section 1841.

“(e) Civil Money Penalty.— In the case of a manufacturer of a part D rebatable drug with an agreement in effect under this section who has failed to comply with the terms of the agreement under subsection (b)(1)(B) with respect to such drug for an applicable year, the Secretary may impose a civil money penalty on such manufacturer in an amount equal to 125 percent of the amount specified in subsection (c) for such drug for such year. The provisions of section 1128A (other than subsections (a) (with respect to amounts of penalties or additional assessments) and (b)) shall apply to a civil money penalty under this subsection in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a).
“(f) Judicial Review.—There shall be no judicial review of the following:

“(1) The determination of units under this section.

“(2) The determination of whether a drug is a part D rebatable drug under this section.

“(3) The calculation of the rebate amount under this section.

“(g) Definitions.—In this section:

“(1) Part D rebatable drug defined.—

“(A) In general.—The term ‘part D rebatable drug’ means a drug or biological that would (without application of this section) be a covered part D drug, except such term shall, with respect to an applicable year, not include such a drug or biological if the average total cost under a prescription drug plan under this part or MA–PD plan under part C for such year per individual who uses such a drug or biological, as determined by the Secretary, are less than, subject to subparagraph (B), $100, as determined by the Secretary using the most recent data available or, if data is not available, as estimated by the Secretary.
“(B) INCREASE.—The dollar amount applied under subparagraph (A)—

“(i) for 2023, shall be the dollar amount specified under such subparagraph for 2022, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) as of January of 2022; and

“(ii) for a subsequent year, shall be the dollar amount specified in this subparagraph (or subparagraph (A)) for the previous year, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) as of January of the previous year.

Any dollar amount specified under this subparagraph that is not a multiple of $10 shall be rounded to the nearest multiple of $10.

“(2) UNIT DEFINED.—The term ‘unit’ means, with respect to a part D rebatable drug, the lowest identifiable quantity (such as a capsule or tablet, milligram of molecules, or grams) of the part D rebatable drug that is dispensed to individuals enrolled under a prescription drug plan under this part or an MA–PD plan under part C.
“(3) Payment amount benchmark year.—The term ‘payment amount benchmark year’ means the year beginning January 1, 2016.

“(4) Benchmark period CPI–U.—The term ‘benchmark period CPI–U’ means the consumer price index for all urban consumers (United States city average) for January 2016.

“(5) Rebate period CPI–U.—The term ‘rebate period CPI–U’ means, with respect to an applicable year, the consumer price index for all urban consumers (United States city average) for January of such year.

“(6) Average manufacturer price.—The term ‘average manufacturer price’ has the meaning, with respect to a part D rebatable drug of a manufacturer for an applicable year, given such term in section 1927(k)(1), with respect to a covered outpatient drug of a manufacturer for a rebate period under section 1927. For purposes of applying the previous sentence, with respect to a part D rebatable drug of a manufacturer and an applicable year, the Secretary shall use the information with respect to the average manufacturer price for such drug reported by the manufacturer under section 1927(b)(3) with respect to each of the quarters in
the applicable year and calculate an annual average manufacturer price for such applicable year as the average of such average manufacturer prices for each such quarter, weighted by units of such drug sold or dispensed with respect to such applicable year.”.

**TITLE III—PART D IMPROVEMENTS AND MAXIMUM OUT-OF-POCKET CAP FOR MEDICARE BENEFICIARIES**

**SEC. 301. MEDICARE PART D BENEFIT REDESIGN.**

(a) **Benefit Structure Redesign.**—Section 1860D–2(b) of the Social Security Act (42 U.S.C. 1395w–102(b)) is amended—

(1) in paragraph (2)—

(A) in subparagraph (A), in the matter preceding clause (i), by inserting “for a year preceding 2022 and for costs above the annual deductible specified in paragraph (1) and up to the annual out-of-pocket threshold specified in paragraph (4)(B) for 2022 and each subsequent year” after “paragraph (3)”;

(B) in subparagraph (C)—

(i) in clause (i), in the matter preceding subclause (I), by inserting “for a
year preceding 2022,” after “paragraph (4),”; and

(ii) in clause (ii)(III), by striking “and each subsequent year” and inserting “and 2021”; and

(C) in subparagraph (D)—

(i) in clause (i)—

(I) in the matter preceding subclause (I), by inserting “for a year preceding 2022,” after “paragraph (4),”; and

(II) in subclause (I)(bb), by striking “a year after 2018” and inserting “each of years 2018 through 2021”; and

(ii) in clause (ii)(V), by striking “2019 and each subsequent year” and inserting “each of years 2019 through 2021”;

(2) in paragraph (3)(A)—

(A) in the matter preceding clause (i), by inserting “for a year preceding 2022,” after “and (4),”; and
(B) in clause (ii), by striking “for a subsequent year” and inserting “for each of years 2007 through 2021”; and
(3) in paragraph (4)—
(A) in subparagraph (A)—
(i) in clause (i)—
(I) by redesignating subclauses (I) and (II) as items (aa) and (bb), respectively, and moving the margin of each such redesignated item 2 ems to the right;
(II) in the matter preceding item (aa), as redesignated by subclause (I), by striking “is equal to the greater of—” and inserting “is equal to—
“(I) for a year preceding 2022, the greater of—”; and
(III) by striking the period at the end of item (bb), as redesignated by subclause (I), and inserting “; and”; and
(IV) by adding at the end the following:
“(II) for 2022 and each succeeding year, $0.”; and
(ii) in clause (ii)—

(I) by striking “clause (i)(I)” and inserting “clause (i)(I)(aa)”; and

(II) by adding at the end the following new sentence: “The Secretary shall continue to calculate the dollar amounts specified in clause (i)(I)(aa), including with the adjustment under this clause, after 2021 for purposes of section 1860D–14(a)(1)(D)(iii).”;

(B) in subparagraph (B)—

(i) in clause (i)—

(I) in subclause (V), by striking “or” at the end;

(II) in subclause (VI)—

(aa) by striking “for a subsequent year” and inserting “for 2021”; and

(bb) by striking the period at the end and inserting a semi-colon; and

(III) by adding at the end the following new subclauses:

“(VII) for 2022, is equal to $2,000; or
“(VIII) for a subsequent year, is equal to the amount specified in this subparagraph for the previous year, increased by the annual percentage increase described in paragraph (6) for the year involved.”; and

(ii) in clause (ii), by striking “clause (i)(II)” and inserting “clause (i)”;

(C) in subparagraph (C)(i), by striking “and for amounts” and inserting “and, for a year preceding 2022, for amounts”; and

(D) in subparagraph (E), by striking “In applying” and inserting “For each of years 2011 through 2021, in applying”.

(b) DECREASING REINSURANCE PAYMENT AMOUNT.—Section 1860D–15(b)(1) of the Social Security Act (42 U.S.C. 1395w–115(b)(1)) is amended by inserting after “80 percent” the following: “(or, with respect to a coverage year after 2021, 20 percent)”.

(e) MANUFACTURER DISCOUNT PROGRAM.—

(1) IN GENERAL.—Part D of title XVIII of the Social Security Act (42 U.S.C. 1395w–101 et seq.), as amended by section 202, is further amended by inserting after section 1860D–14B the following new section:
“SEC. 1860D–14C. MANUFACTURER DISCOUNT PROGRAM.

“(a) Establishment.—The Secretary shall establish a manufacturer discount program (in this section referred to as the ‘program’). Under the program, the Secretary shall enter into agreements described in subsection (b) with manufacturers and provide for the performance of the duties described in subsection (c). The Secretary shall establish a model agreement for use under the program by not later than January 1, 2021, in consultation with manufacturers, and allow for comment on such model agreement.

“(b) Terms of Agreement.—

“(1) In general.—

“(A) Agreement.—An agreement under this section shall require the manufacturer to provide applicable beneficiaries access to discounted prices for applicable drugs of the manufacturer that are dispensed on or after January 1, 2022.

“(B) Provision of discounted prices at the point-of-sale.—The discounted prices described in subparagraph (A) shall be provided to the applicable beneficiary at the pharmacy or by the mail order service at the point-of-sale of an applicable drug.

“(C) Timing of agreement.—
“(i) Special rule for 2022.—In order for an agreement with a manufacturer to be in effect under this section with respect to the period beginning on January 1, 2022, and ending on December 31, 2022, the manufacturer shall enter into such agreement not later than 30 days after the date of the establishment of a model agreement under subsection (a).

“(ii) 2023 and subsequent years.—In order for an agreement with a manufacturer to be in effect under this section with respect to plan year 2023 or a subsequent plan year, the manufacturer shall enter into such agreement (or such agreement shall be renewed under paragraph (4)(A)) not later than January 30 of the preceding year.

“(2) Provision of appropriate data.—Each manufacturer with an agreement in effect under this section shall collect and have available appropriate data, as determined by the Secretary, to ensure that it can demonstrate to the Secretary compliance with the requirements under the program.
“(3) Compliance with requirements for administration of program.—Each manufacturer with an agreement in effect under this section shall comply with requirements imposed by the Secretary or a third party with a contract under subsection (d)(3), as applicable, for purposes of administering the program, including any determination under subparagraph (A) of subsection (c)(1) or procedures established under such subsection (c)(1).

“(4) Length of agreement.—

“(A) In general.—An agreement under this section shall be effective for an initial period of not less than 12 months and shall be automatically renewed for a period of not less than 1 year unless terminated under subparagraph (B).

“(B) Termination.—

“(i) By the Secretary.—The Secretary may provide for termination of an agreement under this section for a knowing and willful violation of the requirements of the agreement or other good cause shown. Such termination shall not be effective earlier than 30 days after the date of notice to the manufacturer of such termination.
The Secretary shall provide, upon request, a manufacturer with a hearing concerning such a termination, and such hearing shall take place prior to the effective date of the termination with sufficient time for such effective date to be repealed if the Secretary determines appropriate.

“(ii) By a manufacturer.—A manufacturer may terminate an agreement under this section for any reason. Any such termination shall be effective, with respect to a plan year—

“(I) if the termination occurs before January 30 of a plan year, as of the day after the end of the plan year; and

“(II) if the termination occurs on or after January 30 of a plan year, as of the day after the end of the succeeding plan year.

“(iii) Effectiveness of termination.—Any termination under this sub-paragraph shall not affect discounts for applicable drugs of the manufacturer that
are due under the agreement before the effective date of its termination.

“(iv) NOTICE TO THIRD PARTY.—The Secretary shall provide notice of such termination to a third party with a contract under subsection (d)(3) within not less than 30 days before the effective date of such termination.

“(c) DUTIES DESCRIBED.—The duties described in this subsection are the following:

“(1) ADMINISTRATION OF PROGRAM.—Administering the program, including—

“(A) the determination of the amount of the discounted price of an applicable drug of a manufacturer;

“(B) the establishment of procedures under which discounted prices are provided to applicable beneficiaries at pharmacies or by mail order service at the point-of-sale of an applicable drug;

“(C) the establishment of procedures to ensure that, not later than the applicable number of calendar days after the dispensing of an applicable drug by a pharmacy or mail order service, the pharmacy or mail order service is
reimbursed for an amount equal to the difference between—

“(i) the negotiated price of the applicable drug; and

“(ii) the discounted price of the applicable drug;

“(D) the establishment of procedures to ensure that the discounted price for an applicable drug under this section is applied before any coverage or financial assistance under other health benefit plans or programs that provide coverage or financial assistance for the purchase or provision of prescription drug coverage on behalf of applicable beneficiaries as the Secretary may specify; and

“(E) providing a reasonable dispute resolution mechanism to resolve disagreements between manufacturers, applicable beneficiaries, and the third party with a contract under subsection (d)(3).

“(2) MONITORING COMPLIANCE.—

“(A) IN GENERAL.—The Secretary shall monitor compliance by a manufacturer with the terms of an agreement under this section.
“(B) Notification.—If a third party with a contract under subsection (d)(3) determines that the manufacturer is not in compliance with such agreement, the third party shall notify the Secretary of such noncompliance for appropriate enforcement under subsection (e).

“(3) Collection of data from prescription drug plans and MA–PD plans.—The Secretary may collect appropriate data from prescription drug plans and MA–PD plans in a timeframe that allows for discounted prices to be provided for applicable drugs under this section.

“(d) Administration.—

“(1) In general.—Subject to paragraph (2), the Secretary shall provide for the implementation of this section, including the performance of the duties described in subsection (c).

“(2) Limitation.—In providing for the implementation of this section, the Secretary shall not receive or distribute any funds of a manufacturer under the program.

“(3) Contract with third parties.—The Secretary shall enter into a contract with 1 or more third parties to administer the requirements established by the Secretary in order to carry out this
section. At a minimum, the contract with a third
party under the preceding sentence shall require
that the third party—

“(A) receive and transmit information be-
tween the Secretary, manufacturers, and other
individuals or entities the Secretary determines
appropriate;

“(B) receive, distribute, or facilitate the
distribution of funds of manufacturers to ap-
propriate individuals or entities in order to
meet the obligations of manufacturers under
agreements under this section;

“(C) provide adequate and timely informa-
tion to manufacturers, consistent with the
agreement with the manufacturer under this
section, as necessary for the manufacturer to
fulfill its obligations under this section; and

“(D) permit manufacturers to conduct
periodic audits, directly or through contracts, of
the data and information used by the third
party to determine discounts for applicable
drugs of the manufacturer under the program.

“(4) PERFORMANCE REQUIREMENTS.—The
Secretary shall establish performance requirements
for a third party with a contract under paragraph
(3) and safeguards to protect the independence and
integrity of the activities carried out by the third
party under the program under this section.

“(5) IMPLEMENTATION.—The Secretary may
implement the program under this section by pro-
gram instruction or otherwise.

“(6) ADMINISTRATION.—Chapter 35 of title 44,
United States Code, shall not apply to the program
under this section.

“(e) ENFORCEMENT.—

“(1) AUDITS.—Each manufacturer with an
agreement in effect under this section shall be sub-
ject to periodic audit by the Secretary.

“(2) CIVIL MONEY PENALTY.—

“(A) IN GENERAL.—The Secretary may
impose a civil money penalty on a manufacturer
that fails to provide applicable beneficiaries dis-
counts for applicable drugs of the manufacturer
in accordance with such agreement for each
such failure in an amount the Secretary deter-
mines is commensurate with the sum of—

“(i) the amount that the manufac-
turer would have paid with respect to such
discounts under the agreement, which will
then be used to pay the discounts which
the manufacturer had failed to provide; and

“(ii) 25 percent of such amount.

“(B) APPLICATION.—The provisions of section 1128A (other than subsections (a) and (b)) shall apply to a civil money penalty under this paragraph in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a).

“(f) CLARIFICATION REGARDING AVAILABILITY OF OTHER COVERED PART D DRUGS.—Nothing in this section shall prevent an applicable beneficiary from purchasing a covered part D drug that is not an applicable drug (including a generic drug or a drug that is not on the formulary of the prescription drug plan or MA–PD plan that the applicable beneficiary is enrolled in).

“(g) DEFINITIONS.—In this section:

“(1) APPLICABLE BENEFICIARY.—The term ‘applicable beneficiary’ means an individual who, on the date of dispensing a covered part D drug—

“(A) is enrolled in a prescription drug plan or an MA–PD plan;

“(B) is not enrolled in a qualified retiree prescription drug plan; and
“(C) has incurred costs for covered part D drugs in the year that are equal to or exceed the annual deductible specified in section 1860D–2(b)(1) for such year.

“(2) APPLICABLE DRUG.—The term ‘applicable drug’, with respect to an applicable beneficiary—

“(A) means a covered part D drug—

“(i) approved under a new drug application under section 505(b) of the Federal Food, Drug, and Cosmetic Act or, in the case of a biologic product, licensed under section 351 of the Public Health Service Act; and

“(ii)(I) if the PDP sponsor of the prescription drug plan or the MA organization offering the MA–PD plan uses a formulary, which is on the formulary of the prescription drug plan or MA–PD plan that the applicable beneficiary is enrolled in;

“(II) if the PDP sponsor of the prescription drug plan or the MA organization offering the MA–PD plan does not use a formulary, for which benefits are available under the prescription drug plan or MA–
PD plan that the applicable beneficiary is
enrolled in; or
“(III) is provided through an exception or appeal; and
“(B) does not include a selected drug (as defined in section 1192(c)) during a price applicability period (as defined in section 1191(b)(2)) with respect to such drug.
“(3) APPLICABLE NUMBER OF CALENDAR DAYS.—The term ‘applicable number of calendar days’ means—
“(A) with respect to claims for reimbursement submitted electronically, 14 days; and
“(B) with respect to claims for reimbursement submitted otherwise, 30 days.
“(4) DISCOUNTED PRICE.—
“(A) IN GENERAL.—The term ‘discounted price’ means, with respect to an applicable drug of a manufacturer furnished during a year to an applicable beneficiary—
“(i) who has not incurred costs for covered part D drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section 1860D—
2(b)(4)(B)(i) for the year, 90 percent of the negotiated price of such drug; and

“(ii) who has incurred such costs in the year that are equal to or exceed such threshold for the year, 70 percent of the negotiated price of such drug.

“(B) CLARIFICATION.—Nothing in this section shall be construed as affecting the responsibility of an applicable beneficiary for payment of a dispensing fee for an applicable drug.

“(C) SPECIAL CASE FOR CERTAIN CLAIMS.—

“(i) CLAIMS SPANNING DEDUCTIBLE.—In the case where the entire amount of the negotiated price of an individual claim for an applicable drug with respect to an applicable beneficiary does not fall at or above the annual deductible specified in section 1860D–2(b)(1) for the year, the manufacturer of the applicable drug shall provide the discounted price under this section on only the portion of the negotiated price of the applicable drug that falls at or above such annual deductible.
“(ii) Claims spanning out-of-pocket threshold.—In the case where the entire amount of the negotiated price of an individual claim for an applicable drug with respect to an applicable beneficiary does not fall entirely below or entirely above the annual out-of-pocket threshold specified in section 1860D–2(b)(4)(B)(i) for the year, the manufacturer of the applicable drug shall provide the discounted price—

“(I) in accordance with subparagraph (A)(i) on the portion of the negotiated price of the applicable drug that falls below such threshold; and

“(II) in accordance with subparagraph (A)(ii) on the portion of such price of such drug that falls at or above such threshold.

“(5) Manufacturer.—The term ‘manufacturer’ means any entity which is engaged in the production, preparation, propagation, compounding, conversion, or processing of prescription drug products, either directly or indirectly by extraction from substances of natural origin, or independently by
means of chemical synthesis, or by a combination of
eextraction and chemical synthesis. Such term does
not include a wholesale distributor of drugs or a re-
tail pharmacy licensed under State law.

“(6) NEGOTIATED PRICE.—The term ‘nego-
tiated price’ has the meaning given such term in sec-
tion 423.100 of title 42, Code of Federal Regula-
tions (as in effect on the date of enactment of sec-
tion 1860D–14A), except that such negotiated price
shall not include any dispensing fee for the applica-
ble drug.

“(7) QUALIFIED RETIREE PRESCRIPTION DRUG
PLAN.—The term ‘qualified retiree prescription drug
plan’ has the meaning given such term in section
1860D–22(a)(2).”.

(2) SUNSET OF MEDICARE COVERAGE GAP DIS-
COUNT PROGRAM.—Section 1860D–14A of the So-
cial Security Act (42 U.S.C. 1395–114a) is amend-
ed—

(A) in subsection (a), in the first sentence,
by striking “The Secretary” and inserting
“Subject to subsection (h), the Secretary”; and

(B) by adding at the end the following new
subsection:

“(h) SUNSET OF PROGRAM.—
“(1) IN GENERAL.—The program shall not apply with respect to applicable drugs dispensed on or after January 1, 2022, and, subject to paragraph (2), agreements under this section shall be terminated as of such date.

“(2) CONTINUED APPLICATION FOR APPLICABLE DRUGS DISPENSED PRIOR TO SUNSET.—The provisions of this section (including all responsibilities and duties) shall continue to apply after January 1, 2022, with respect to applicable drugs dispensed prior to such date.”.

(3) INCLUSION OF ACTUARIAL VALUE OF MANUFACTURER DISCOUNTS IN BIDS.—Section 1860D–11 of the Social Security Act (42 U.S.C. 1395w–111) is amended—

(A) in subsection (b)(2)(C)(iii)—

(i) by striking “assumptions regarding the reinsurance” and inserting “assumptions regarding—

“(I) the reinsurance”; and

(ii) by adding at the end the following:

“(II) for 2022 and each subsequent year, the manufacturer discounts provided under section 1860D–
14C subtracted from the actuarial value to produce such bid; and''; and

(B) in subsection (c)(1)(C)—

(i) by striking “an actuarial valuation of the reinsurance” and inserting “an actuarial valuation of—

“(i) the reinsurance”;

(ii) in clause (i), as inserted by clause (i) of this subparagraph, by adding “and” at the end; and

(iii) by adding at the end the following:

“(ii) for 2022 and each subsequent year, the manufacturer discounts provided under section 1860D–14C;”.

(d) CONFORMING AMENDMENTS.—

(1) Section 1860D–2 of the Social Security Act (42 U.S.C. 1395w–102) is amended—

(A) in subsection (a)(2)(A)(i)(I), by striking “, or an increase in the initial” and inserting “or, for a year preceding 2022, an increase in the initial”; and

(B) in subsection (c)(1)(C)—

(i) in the subparagraph heading, by striking “AT INITIAL COVERAGE LIMIT”; and

(ii) by inserting “for a year preceding 2022 or the annual out-of-pocket threshold specified in subsection (b)(4)(B) for the year for 2022 and each subsequent year” after “subsection (b)(3) for the year” each place it appears; and

(C) in subsection (d)(1)(A), by striking “or an initial” and inserting “or, for a year preceding 2022, an initial”.

(2) Section 1860D–4(a)(4)(B)(i) of the Social Security Act (42 U.S.C. 1395w–104(a)(4)(B)) is amended by striking “the initial” and inserting “for a year preceding 2022, the initial”.

(3) Section 1860D–14(a) of the Social Security Act (42 U.S.C. 1395w–114(a)) is amended—

(A) in paragraph (1)—

(i) in subparagraph (C), by striking “The continuation” and inserting “For a year preceding 2022, the continuation”; and

(iii) in subparagraph (E), by striking “The elimination” and inserting “For a year preceding 2022, the elimination”; and (B) in paragraph (2)—

(i) in subparagraph (C), by striking “The continuation” and inserting “For a year preceding 2022, the continuation”; and

(ii) in subparagraph (E)—

(I) by inserting “for a year preceeding 2022,” after “subsection (c)”;

and


(A) by striking “the value of any discount” and inserting the following: “the value of—
“(i) for years prior to 2022, any dis-
count”.

(B) in clause (i), as inserted by subpara-
graph (A) of this paragraph, by striking the pe-
riod at the end and inserting “; and”; and

(C) by adding at the end the following new
clause:

“(ii) for 2022 and each subsequent
year, any discount provided pursuant to
section 1860D–14C.”.

(6) Section 1860D–41(a)(6) of the Social Secu-
rity Act (42 U.S.C. 1395w–151(a)(6)) is amended—

(A) by inserting “for a year before 2022”
after “1860D–2(b)(3)”; and

(B) by inserting “for such year” before the
period.

(7) Paragraph (1) of section 1860D–43(a) of
the Social Security Act (42 U.S.C. 1395w–153(a)) is
amended to read as follows:

“(1) participate in—

“(A) for 2011 through 2021, the Medicare
coverage gap discount program under section
1860D–14A; and
“(B) for 2022 and each subsequent year, the manufacturer discount program under section 1860D–14C;”.

(e) EFFECTIVE DATE.—The amendments made by this section shall apply with respect to plan year 2022 and subsequent plan years.